Cytori Therapeutics, Inc. (USA) (CYTX)
$5.15
0.21 (+4.25%)
| CAPS Rating |
|
|---|---|
| Open | $0.00 |
| Previous Close | $5.15 |
| Daily Range | $4.68 - $5.24 |
| 52-Week Range | $1.42 - $5.14 |
| Market Cap | $199.58M |
| P/E Ratio | 0.00 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 628,403 |
| Average Daily Volume | 344,000 |
CYTX
VS S&P 500 (SPY)
How do you think CYTX will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
CYTX Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
CYTX News and Commentary
- 4-Star Stocks Poised to Pop: Cytori Therapeutics – The Motley Fool
- 5-Star Stocks on the Upswing – The Motley Fool
- 4-Star Stocks on the Upswing – The Motley Fool
- A Big Upgrade for Cytori Therapeutics – The Motley Fool
- 5 Cold Stocks Heating Up – The Motley Fool
- Tomorrow's Monster Stocks? – The Motley Fool
- A Less-Risky Stem Cell Play – The Motley Fool
- 5 Stocks Approaching Greatness – The Motley Fool
- Stem Cell Stocks Surge in Past Month – Blog at The Motley Fool
- Trading the Trials: Cytori and Cypress Bio – Blog at The Motley Fool
- Regenerative Medicine: The Next Frontier for Big Pharma – Blog at The Motley Fool
- Cytori Therapeutics: Set for a Sale to Olympus? – Blog at The Motley Fool
- Drop-Dead Gorgeous Stocks – The Motley Fool
- The Stem Cell 'Celution' for Success at Cytori Therapeutics – Blog at The Motley Fool
- 5 Stocks Approaching Greatness – The Motley Fool
- The Fear Trade: Investors Pile into Gold and Treasuries – Blog at The Motley Fool
- Cytori's Stem Cell 'Celution' for Success – Blog at The Motley Fool
- Cytori Therapeutics (CYTX) Relieves Funding Concern & Announces 2Q08 Operating Results – Blog at The Motley Fool
- Cytori Therapeutics: The Stem Cell 'Celution' for Success – Blog at The Motley Fool
- The Stem Cell Celution® for Success at Cytori Therapeutics – Blog at The Motley Fool
RSS Headlines
Fool UK
